Botulinum toxin type A for prophylactic treatment of chronic migraine
Kim M, Danielsson A, Ekelund A-C, Kemppainen E, Sjögren P, Svanberg T, Szalo G, Samuelsson O
Record ID 32016000590
English
Authors' recommendations:
It is uncertain whether BTX reduces the frequency of headache days, reduces acute headache pain medication, or has any impact on functioning in comparison with saline. Botulin toxin A injection may result in little or no difference in the number of headache episodes, headache hours and quality of life in comparison to saline injections.
It cannot be excluded that saline injections per se have beneficial effects on chronic migraine.
The effects of repeated BTX injections during more than one year follow-up are not known.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
https://www2.sahlgrenska.se/upload/SU/HTA-centrum/HTA-rapporter/HTA-report%20Botulinum%20toxin%20type%20A%20for%20Prophylactic%20Treatment%20till%20publicering%202014-05-23.pdf
URL for additional information:
http://www.sahlgrenska.se/sv/SU/Forskning/HTA-centrum/Hogerkolumn-undersidor/Publicerade-rapporter/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
MeSH Terms
- Humans
- Botulinum Toxins, Type A
- Migraine Disorders
- Neuromuscular Agents
Contact
Organisation Name:
The Regional Health Technology Assessment Centre
Contact Address:
The Regional Health Technology Assessment Centre, Region Vastra Gotaland, HTA-centrum, Roda Straket 8, Sahlgrenska Universitetssjukhuset, 413 45 GOTHENBORG, Sweden
Contact Name:
hta-centrum@vgregion.se
Contact Email:
hta-centrum@vgregion.se
Copyright:
The Regional Health Technology Assessment Centre (HTA-centrum), Region Vastra Gotaland
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.